NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from Guangzhou Aoyu? Mail in a sample (US only) and let us test it.

Test my supply
52%
Finnrick rating
#472 of 489 ranked vendors
10 of 24 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Guangzhou Aoyu's purity-focus record is narrow and mixed, with Tirzepatide showing earlier clean 99.9% purity results but no broader peptide coverage. Recent Tirzepatide evidence is highly dispersed, as repeated June identity failures with 0% purity and no fill offset one clean mid-June result.

methodology →
vendor intelligence report
Vendor Intelligence Report: Guangzhou Aoyu

Corporate records put the peptide storefront on a platform-only GlobalSources profile while older Aoyu listings sell unrelated goods. The report maps the identity stack, manufacturer-claim conflicts, missing credential trail, and clean-but-limited promotion sweep.

19 pages4 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.82
74%
6
2
Tirzepatide
$0.40
60%
13
3
Tesamorelin
$1.45
41%
3
4
MOTS-c
-
32%
2
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%28 Apr 2026: 80%6 May 2026: 81%19 May 2026: 80%20 May 2026: 67%27 May 2026: 61%4 Jun 2026: 60%6 Jun 2026: 59%8 Jun 2026: 59%15 Jun 2026: 60%15 Jun 2026: 60%16 Jun 2026: 59%16 Jun 2026: 58%26 Jun 2026: 59%26 Jun 2026: 59%22 Jul 2026: 59%3 Aug 2026: 58%24 Sep 2026: 58%6 Oct 2026: 57%6 Oct 2026: 56%15 Oct 2026: 55%20 Oct 2026: 56%20 Oct 2026: 55%20 Oct 2026: 54%20 Oct 2026: 53%23 Oct 2026: current 52%80%59%52%Apr 26Oct 26
Free peptide testing

Ordered peptides from Guangzhou Aoyu? Mail in a sample (US only) and let us test it.

Test my supply
Guangzhou Aoyu test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
20 Oct 2026
Fail
Tirzepatide
lab nameView COA
20 Oct 2026
Fail
Tirzepatide
lab nameView COA
20 Oct 2026
Fail
Tirzepatide
lab nameView COA
20 Oct 2026
Pass
Tirzepatide
lab nameView COA
15 Oct 2026
Fail
Retatrutide
lab nameView COA
6 Oct 2026
Fail
Tirzepatide
lab nameView COA
6 Oct 2026
Fail
Retatrutide
lab nameView COA
24 Sep 2026
Pass
Retatrutide
lab nameView COA
3 Aug 2026
Fail
Tesamorelin
lab nameView COA
22 Jul 2026
Pass
Retatrutide
lab nameView COA
1-10 of 24

About Guangzhou Aoyu test results from Finnrick

Guangzhou Aoyu is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 4 peptides and 24 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Guangzhou Aoyu peptides in this dataset are Tirzepatide (13 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 24 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from Guangzhou Aoyu? Mail in a sample (US only) and let us test it.

Test my supply